Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
503
Frequently Asked Questions
Market cap, also known as market capitalization, is the total market value of a company. It's calculated by multiplying the current market price by the total number of shares outstanding. Denali Therapeutics Inc market cap is $3B.
52 week high is the highest price of a stock in the past 52 weeks, or one year. Denali Therapeutics Inc 52 week high is $27.30 as of November 17, 2026.
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Denali Therapeutics Inc 52 week low is $15.34 as of November 17, 2026.
Denali Therapeutics Inc stock price today is $18.08.
Denali Therapeutics Inc stock price yesterday was $18.74.
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It's calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company's Market Cap by the Net Profit. Denali Therapeutics Inc's P/E ratio is -10.41.
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It's calculated by dividing a company's market capitalization by its book value. Denali Therapeutics Inc P/B ratio is 3.1277.
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It's calculated by averaging the closing stock price over the previous 50 trading days. Denali Therapeutics Inc 50-day moving average is $19.69.